等待開盤 10-10 09:30:00 美东时间
0.000
0.00%
Liquidia Corporation will host an R&D Day on October 28, 2025, in New York City, featuring presentations by its management and three key opinion leaders in pulmonary hypertension. The focus will be on L606, an investigational sustained-release treprostinil formulation, and YUTREPIA™, its approved inhaled treprostinil powder. The event aims to highlight progress in improving patient outcomes for those with pulmonary arterial hypertension (PAH) and...
10-07 10:30
J.P. Morgan Asset Management launches three new active ETFs using data science for portfolio construction on Nasdaq.
2024-08-09 02:02